Boston Scientific inks $600M Augmenix buyout

Boston Scientific inks $600M Augmenix buyout

Source: 
Biopharma Dive
snippet: 

Boston Scientific has struck a $600 million deal to acquire Augmenix for a device that reduces the side effects of prostate cancer radiotherapy.